UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 19, 2014
AVALANCHE BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware | 001-36579 | 20-5258327 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification Number) |
1035 OBrien Drive, Suite A
Menlo Park, CA 94025
(650) 272-6269
(Address of principal executive offices, including Zip Code)
Registrants telephone number, including area code: (650) 272-6269
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 7.01. | Regulation FD Disclosure. |
On September 19, 2014, Avalanche Biotechnologies, Inc. (the Company) issued a press release announcing that Thomas W. Chalberg, Jr., Ph.D., its Founder and Chief Executive Officer, will present at the 21st Annual NewsMakers in the Biotech Industry conference on Friday, September 26, 2014 at 10:30 a.m. Eastern Time in New York, New York. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.
The information furnished pursuant to this Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Securities Exchange Act of 1934, as amended, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered filed or incorporated by reference therein.
Item 9.01. | Financial Statements and Exhibits. |
(d) | Exhibits. |
Exhibit No. |
Description | |
99.1 | Press Release dated September 19, 2014 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 22, 2014 | AVALANCHE BIOTECHNOLOGIES, INC. | |||||
By: | /s/ Linda C. Bain | |||||
Linda C. Bain | ||||||
Chief Financial Officer |
EXHIBIT INDEX
Exhibit No. |
Description | |
99.1 | Press Release dated September 19, 2014 |
Exhibit 99.1
Avalanche Biotechnologies to Present at the NewsMakers in the Biotech Industry Conference
MENLO PARK, Calif., Sept. 19, 2014 (GLOBE NEWSWIRE) Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Thomas W. Chalberg, Jr., Ph.D., Founder and Chief Executive Officer, will present at the 21st Annual NewsMakers in the Biotech Industry conference on Friday, September 26, 2014 at 10:30 AM (EDT) in New York, NY.
A live webcast of the presentation will be accessible under Events & Presentations in the Investors section of Avalanches website. Avalanche will maintain an archived replay of the webcast on its website for two weeks after the conference.
About Avalanche Biotechnologies, Inc.
Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Avalanches lead product, AVA-101, is currently under development in a Phase 2a trial for wet AMD. Avalanches Ocular BioFactory platform technology is a proprietary adeno-associated virus (AAV)-based gene therapy discovery and development technology optimized for ophthalmology that utilizes a directed evolution approach to generate novel drug candidates. For more information please visit www.avalanchebiotech.com.
Investor Contact:
Chris Erdman
MacDougall Biomedical Communications
(781) 235-3060
Media Contact:
Kathy Vincent
(310) 403-8951